A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00868361
Recruitment Status : Terminated (Poor recruitment of fast and slow acetylators)
First Posted : March 25, 2009
Last Update Posted : September 16, 2009
Information provided by:
Teva Pharmaceutical Industries

Brief Summary:
The purpose of this study is to characterize the chemical breakdown and excretion of talampanel and its break down products in plasma, feces, and urine of healthy human volunteers.

Condition or disease Intervention/treatment Phase
Healthy Drug: Talampanel (non-radiolabeled), [14C] Talampanel Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open-label Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Talampanel Following Oral Administration to Healthy Male
Study Start Date : May 2009
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Arm Intervention/treatment
Experimental: Slow and rapid N-acetyl transferase genotypes Drug: Talampanel (non-radiolabeled), [14C] Talampanel
50 mg capsule single dose
Other Name: TV-7600

Primary Outcome Measures :
  1. To determine the mass balance of [14C]-talampanel. To characterize the metabolism of [14C] talampanel in plasma, feces, and urine. To assess the pharmacokinetics (PK) of total radioactivity, talampanel, and N-acetyl talampanel. [ Time Frame: 6-9 days ]

Secondary Outcome Measures :
  1. To explore the effect of N-acetyltransferase 2 (NAT2) genotype on the PK and metabolism of [14C] talampanel. To further assess the safety and tolerability of talampanel. [ Time Frame: 6-9 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males, between 18 and 55 years of age, inclusive
  • Body Mass Index range 18.0 to 30.0 kg/m2, inclusive
  • Have NAT2 slow or rapid acetylator genotype
  • In good health as determined by the investigator
  • Negative test for selected drugs of abuse at screening
  • Negative screens for Hepatitis B, Hepatitis C and HIV
  • Sterile or agrees to use an approved method of contraception from Check-in until 45 days following Clinic Discharge
  • Able to comprehend and willing to sign an Informed Consent Form
  • Have 1 to 2 bowel movements per day

Exclusion Criteria:

  • Significant history or clinical manifestation of any significant metabolic, allergic, skin, liver, kidney, blood, heart or blood vessel, digestive system, brain or psychiatric disorder
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
  • History of stomach or intestinal surgery or resection
  • History or presence of an abnormal ECG,
  • History of clinically significant alcohol or drug use within 1 year prior to Check-in
  • Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in
  • Exposure to significant radiation within 12 months prior to Check-in -Use of any tobacco- or nicotine-containing within 6 months prior to Check- in
  • Use of any drugs which may interact with the study drug within 30 days prior to Check-in
  • Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Check-in
  • Use of any prescription medications/products within 14 days prior to Check in
  • Use of any over-the-counter, non-prescription drugs within 7 days prior to Check-in
  • Use of grapefruit or grapefruit-containing foods or beverages within 7 days prior to Check-in
  • Use of alcohol- or caffeine-containing foods or beverages within 72 hours prior to Check-in
  • Donation of blood from 30 days prior to Screening through Study Completion, inclusive, or of plasma from 2 weeks prior to Screening through Study Completion
  • Receipt of blood products within 2 months prior to Check-in
  • Any acute or chronic condition that would limit the subject's ability to complete and/or participate in this clinical study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00868361

United States, Wisconsin
Covance Clinical Pharmacology Inc.
Madison, Wisconsin, United States, 53704
Sponsors and Collaborators
Teva Pharmaceutical Industries
Principal Investigator: Nicholas M Siebers, MD Covance

Responsible Party: Siyu Liu, M.D., Ph.D., Vice President, Innovative Research and Development and Head of Global Clinical Operations Identifier: NCT00868361     History of Changes
Other Study ID Numbers: TAL-MB-100
First Posted: March 25, 2009    Key Record Dates
Last Update Posted: September 16, 2009
Last Verified: September 2009

Keywords provided by Teva Pharmaceutical Industries:
Mass Balance
Healthy Volunteers